Mérieux Equity Partners is a prominent European investment firm based in Lyon, France, focusing on the healthcare and nutrition sectors. Established in 2009, the firm manages over €1.5 billion in assets through various funds dedicated to venture capital, growth, and buyout investments. It supports innovative medical solutions and health products, investing in companies ranging from early-stage startups to established leaders primarily in Europe and North America. The firm operates through multiple platforms, including a Venture Capital Platform that targets seed to Series B funding for diagnostic and therapeutic innovations, and a Growth/Buyout Platform that invests in more mature companies. Additionally, Mérieux Equity Partners has a Venture Studio, M2care, which co-develops early-stage HealthTech projects. The company partners closely with entrepreneurs and management teams, providing not only capital but also operational expertise and access to a broad network in the healthcare industry. With a dedicated team of professionals, Mérieux Equity Partners is committed to fostering growth and innovation in the healthcare and nutrition sectors.
我们正在追踪 Merieux Equity Partners 的市场扩张
Merieux Equity Partners 的国际扩张与竞争对手的对比情况
Merieux Equity Partners你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Merieux Equity Partners你 | 0 | 0 | — | 0 | 0 |
Marketing & Communication Specialist
查看职位Lyon, Auvergne-Rhône-Alpes, France · 去年
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
诺基因从Mérieux Equity Partners收购Theravia，加强其罕见病药物组合和在欧洲特种药品市场的地位。
Ceva动物健康重组资本，投资者信心renewed，管理层保持控制权和独立性，同时欢迎新投资者支持全球增长和创新。
DeepUll完成5000万欧元C轮融资,用于快速败血症诊断。由Columbus、Panakès、Mérieux领投。UllCORE系统可在1小时内检测病原体。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Merieux Equity Partners 的业务、市场和增长信号的快速解答。
